Brief: FDA Accepts Application For Roche's Gazyva/Gazyvaro For Treatment Of Lupus
21/04/2026 06:03
April 21 (Reuters) - Roche Holding AG ROPC.S: FDA ACCEPTS APPLICATION FOR ROCHE’S GAZYVA/GAZYVARO FOR THE TREATMENT OF THE MOST COMMON FORM OF LUPUS ROCHE HOLDING AG - FILING ACCEPTANCE BASED ON PHASE III ALLEGORY STUDY SHOWING SIGNIFICANT SRI-4 BENEFIT AT 52 WEEKS ROCHE HOLDING AG - FDA EXPECTED TO MAKE APPROVAL DECISION BY DECEMBER 2026 Source text: ID:nGNEb5Gdzv Further company coverage: ROPC.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Roche Holding AG
See all newsTable: Swiss trade surplus at CHF 6.11 bln in May
Brief: Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination
Swiss stocks - Factors to watch on June 18
FDA approves first generic version of Roche's flu drug
Brief: FDA Approves First Single-Dose Generic Treatment For Influenza